Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Ovarian Cancer · Immunotherapy · Pembrolizumab

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Obstetrics and Gynecology Hospital of Fudan University, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Wu, Doctor) · wuxin_fc@fudan.edu.cn · 86 13764046908

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1

Houston, United States

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Chicago, United States · Kelowna, Canada

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Colorectal Cancer · Metastatic Pancreatic Cancer · Metastatic Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Bethesda, United States

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Breast Cancer · Endometrial Cancer · Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Orlando, United States · Boston, United States